Clinical Trial Update: Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial investigating an optimised CD33 CAR T cell therapy (FL-33) for refractory/relapsed acute myeloid leukemia; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Optimised CD33 (FL-33) CAR T Therapy

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: Refractory/Relapsed Acute Myeloid Leukaemia | Phase 1 | Status: RECRUITING